SCHEMBL2933217

SCHEMBL2933217

Cc1ccc(C(=O)NC[C@H](NC(=O)c2nccc3ccccc23)C(=O)NCCC(C)C)cc1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.44
NPC1 O15118 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CCR1 P32246 1/20 0.42
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
CTSS P25774 1/20 0.38
CTSK P43235 1/20 0.38
CNR1 P21554 1/20 0.38
POLB P06746 2/20 0.38
LMNA P02545 2/20 0.38
GRM5 P41594 1/20 0.37
CNR2 P34972 3/20 0.37
KDM4A O75164 1/20 0.37
CTDSP1 Q9GZU7 1/20 0.37
KDM4C Q9H3R0 1/20 0.37
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2933213 0.86 CCR1 (0.42) RAB9ACCR1MEN1KMT2APOLB
SCHEMBL2936326 0.84 PSMB5 (0.48) CCR1
SCHEMBL2931864 0.82 KMT2A (0.57) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL2927699 0.80 NPC1 (0.53) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL2931810 0.80 NPC1 (0.45) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL2933907 0.80 NPC1 (0.47) RAB9ANPC1SMN1; SMN2CCR1MEN1
SCHEMBL2934007 0.79 NPC1 (0.46) RAB9ANPC1SMN1; SMN2CTSSCTSK
SCHEMBL2930534 0.79 GRN (0.53) RAB9ANPC1SMN1; SMN2CCR1MEN1
SCHEMBL2933647 0.78 CCR1 (0.49) RAB9ANPC1SMN1; SMN2CCR1MEN1
SCHEMBL2926141 0.78 RAB9A (0.48) RAB9ANPC1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1846424-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-01-27 EP claimed
US-7468383-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2008-12-23 US claimed
US-20060189806-A1 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2006-08-24 US claimed
US-8283367-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2012-10-09 US disclosed
EP-1846424-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-01-27 EP disclosed
US-20090075936-A1 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2009-03-19 US disclosed
US-7468383-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2008-12-23 US disclosed
US-20060189806-A1 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2006-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189806-A1 Proteasome inhibitors and methods of using the same PSMB11, PSMB5, PSMB6 RAB9A 3665/4885NPC1 2169/4885SMN1; SMN2 1069/4885
US-20090075936-A1 Proteasome inhibitors and methods of using the same PSMB11, PSMB5, PSMB6 RAB9A 3665/4885NPC1 2169/4885SMN1; SMN2 1069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.